Erika Martin

Associate Professor of Public Administration and Policy, University at Albany, SUNY
Chapter Member: Central New York SSN
Areas of Expertise:

Connect with Erika

About Erika

Martin's research focuses on the allocation of scarce public health resources, the adoption and impact of public health policies, and improving the sustainability and impact of open data initiatives. Martin's overarching themes include HIV/AIDS and related syndemics, translating evidence-based research into public health practice, co-production of knowledge with government agency staff, and US health policy. Martin's research and commentaries have appeared in leading journals. Martin has served on national and state workgroups on HIV policy and the federal open health data portal, and has presented to numerous practitioner audiences.


In the News

"The Potential Role of Open Data in Mitigating the COVID-19 Pandemic: Challenges and Opportunities," Erika Martin (with Sunyoung Pyo and Luigi Reggi), Health Affairs Blog, November 2, 2020.
"Protecting the Health of Vulnerable Children and Adolescents During COVID-19–Related K-12 School Closures in the US," Erika Martin (with Lucy C. Sorensen), Jama Health Forum, Jama Network, June 16, 2020.
"How to Maintain Momentum on Other Public Health Initiatives Even As COVID-19 Rages: Lessons From Pakistan," Erika Martin (with Hina Khalid), Health Affairs Blog, May 12, 2020.
"No Longer Invisible: The Critical Role of Local Health Departments in Responding to COVID-19," Erika Martin (with Jessica Kronstadt), Health Affairs Blog, April 16, 2020.
Erika Martin quoted on the importance of treating the whole patient and having factors more important than just prescribing HIV medications by Brian Palmer, "We Should Treat Everyone Like We Treat HIV-Positive Patients" Slate, January 16, 2018.
Erika Martin quoted on shortage of organs available for transplant is a major public health problem in the United States, "U.S. Organ-Donor System Needs Overhaul: Study" U.S. News, June 1, 2015.


"A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014–2018" (with Bahareh Ansari, Katherine M Tote, and Eli S Rosenberg). National Center for Biotechnology Information 135 (2020).

Elaborates on the context of rising rates of opioid deaths, evidence is needed about systems-level interventions to curb the opioid epidemic. Conducts a rigorous review of the evidence, finding that robust prescription drug monitoring programs and laws to legalize recreational or medicinal marijuana are promising but do not address all aspects of opioid use disorder, and there is a notable evidence gap on other strategies such as naloxone distribution and changes in clinical guidelines.

"Association of US Households’ Disaster Preparedness With Socioeconomic Characteristics, Composition, and Region" National Center for Biotechnology Information 3, no. 4 (2020).

Shows that despite strong efforts to promote disaster preparedness, many US households continue to have low preparedness for natural and man-made disasters. Mentions that although most households have some level of preparedness, they were more likely to fulfill resource-based items such as food and water stockpiles than action-based items such as having alternative communication plan or meeting location; and the types of preparedness varied across household types.

"Evaluating the Quality and Usability of Open Data for Public Health Research: A Systematic Review of Data Offerings on 3 Open Data Platforms" (with Jennie Law, Weijia Ran, Natalie Helbig, and Guthrie S Birkhead ). National Center for Biotechnology Information 23, no. 4 (2017).

Discusses the government transparency movement and how it has led to increased availability of government datasets on open data platforms that are free of charge and with unlimited use and distribution rights, but their quality and usefulness are unknown.

"Treating and Preventing HIV With Generic Drugs – Barriers in the United States" (with Bruce R Schackman). National Center for Biotechnology Information 378, no. 4 (2018): 316-319.

Discusses the new availability of generic antiretroviral therapy for HIV in the US has the potential to save money for government programs serving the majority of people living with HIV, whose budgets are stretched thin. Unfortunately, optimism about affordable drug therapies needs to be tempered because there are important legal, clinical, and market factors that will delay widespread adoption of generic antiretrovirals, in addition to uncertainty about the actual cost savings to government programs.

"Simulating the End of AIDS in New York: Using Participatory Dynamic Modeling to Improve Implementation of the Ending the Epidemic Initiative" (with Roderick H MacDonald, Daniel E Gordon, Carol-Ann Swain, Travis O'Donnell, John Helmeset , Adenantera Dwicaksono, and James M Tesoriero). National Center for Biotechnology Information 135 (2020).

Discusses the development of a simulation model of New York's HIV epidemic to project the likely impact of the state's ending the Epidemic policy initiative. Mentions findings regarding that New York is on track, but unlikely to meet the benchmark of 750 infections.

"Opening Government Health Data to the Public: Benefits, Challenges, and Lessons Learned From Early Innovators" (with Grace M Begany). National Center for Biotechnology Information 24, no. 2 (2017): 345-351.

Covers following President Obama's memorandum on government transparency, government agencies and how they  have rapidly developed web portals to publish "open" data for use by researchers, civic tech, journalists, and citizens. Shows that early leaders in the US open health data movement reported that while the open data movement has a bright future, its success requires sustained leadership, funding, technical skills, changing organizational culture, promoting data use, and establishing clear policies.